The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
U.S. FDA approves blinatumomab as consolidation for adult and pediatric patients with CD19+ B-ALL, irrespective of MRD status
On June 14, 2024, the U.S. Food and Drug Administration (FDA) approved blinatumomab for the treatment of adult and pediatric patients aged 1 month or older who have CD19-positive, Philadelphia chromosome (Ph)-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase of multiphase chemotherapy, irrespective of measurable residual disease status.1 The decision is based primarily on data from the ECOG-ACRIN E1910 study (NCT02003222), a phase III randomized, controlled trial in adult patients with newly diagnosed, Ph-negative B-ALL, as well as data from study 20120215 (NCT02393859), a randomized, controlled, open-label, multicenter trial including pediatric and young adult patients with Ph-negative BCP ALL.1
Key data
In the ECOG-ACRIN E1910 study, eligible patients in hematologic complete remission (CR) or CR with incomplete peripheral blood count recovery (CRi) following induction and intensification chemotherapy were randomized 1:1 to receive a consolidation regimen of multiple blinatumomab monotherapy cycles plus multiple cycles of intensive chemotherapy (n = 112) or intensive chemotherapy alone (n = 112).1
- Addition of blinatumomab to multiphase consolidation chemotherapy resulted in superior overall survival (OS) vs chemotherapy alone; 3-year OS was 84.8% (95% confidence interval [CI], 76.3–90.4) vs 69% (95% CI, 58.7–77.2) in the blinatumomab and chemotherapy arms, respectively.
- At a median follow-up of 4.5 years, the 5-year OS was 82.4 % (95% CI, 73.7–88.4) in the blinatumomab arm and 62.5 % (95% CI, 52.0–71.3) in the chemotherapy arm.
In study 20120215, patients aged >28 days and <18 years were randomized 1:1 to receive blinatumomab or the IntReALLHR2010 HC3 intensive combination chemotherapy as the third consolidation cycle.1
- The 5-‑year OS was 78.4% (95% CI, 64.2–87.4) vs 41.4% (95% CI, 26.3–55.9) for the blinatumomab and chemotherapy arms, respectively.
- The 5-year relapse-free survival was 61.1% (95% CI, 46.3–72.9) with blinatumomab and 27.6% (95% CI, 16.2–40.3) with chemotherapy.
Conclusion
This FDA approval marks an important clinical development for this patient population, allowing treatment with blinatumomab irrespective of MRD status, redefining the standard of care for patients with B-ALL.1,2
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content